Discover and read the best of Twitter Threads about #ashp18
Most recents (1)
Round 2 of the Great ID Debates of #ASHP18 @ASHPOfficial comes to us from the brilliant minds of @SIDPharm members @TimbrookTT and @julie_justo. To start us off, Tristan makes the case for #fidaxomicin (FID) for treatment of Clostridioides difficile (#cdiff) infection 
.@TimbrookTT sets up the major points for FID in the treatment of #Cdiff: 1- ⬇️recurrence compared to #vancomycin (VAN) in RCTs + ⬆️in cure without recurrence (aka global clinical cure) 2- this held up in real-world data 3- cost-effectiveness analyses support 1st line use #ASHP18
.@TimbrookTT notes the 2018 @IDSAInfo guidelines for #cdiff (idsociety.org/practice-guide…) recommend FID equally to VAN and for first recurrence, quality of evidence is higher 👀🤔#ASHP18
